Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Glimpsing The Birth Of Our Earliest Reproductive Cells
It has long been a mystery how the developing embryo designates those rare, precious cells destined to produce sperm and eggs -- enabling us to have offspring - since these primordial germ cells" existence is fleeting and hard to spot with the tools of biology. Now, using mouse embryonic stem cells, researchers in the Stem Cell Program at Children"s Hospital Boston have managed to recapitulate the creation of primordial germ cells (PGCs) in the lab, capturing the stem cells" gene activity as they differentiated to form PGCs. The findings, published in the July 5 issue of Nature, also offer a unique window on cancer.
generic viagra online
1994 Group Responds To Innovation, Universities, Science and Skills Committee 'Students And Universities' Report
Responding to the Innovation, Universities, Science and Skills Committee (IUSS) report on "Students and Universities" Professor Paul Wellings, Chair of the 1994 Group of leading research intensive universities and Vice-Chancellor of Lancaster University said:
News of the day
Discovery Of Specific Genetic Cause Of Fetal Alcohol-Related Developmental Disorders
Alcohol consumption by pregnant women hinders brain development in their children by interfering with the genetic processes that control thyroid hormone levels in the fetal brain, a new animal study found. Results were presented at The Endocrine Society"s 91st Annual Meeting in Washington, D.C.
Health Insurance

Fate Therapeutics To Present Data On Stimulation Of Osteogenic Activity Using Small Molecule Modulators Of Wnt Pathway

Fate Therapeutics, Inc. announced the presentation of data from its research on small molecule modulators of the Wnt pathway for osteo-regeneration at the 7th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Barcelona, Spain. In its findings, the Company demonstrated that selected Wnt activators induce the differentiation of mesenchymal stem cells to mature, bone-forming osteoblasts. The study highlights the potential for using small molecule Wnt activators as osteogenic agents. Because osteogenic agents stimulate positive bone growth, they may offer an improved course of action in clinical settings ranging from orthopedics to osteoporosis as compared to current medications aimed at preventing bone decay. "By applying our knowledge of adult stem cell biology to mesenchymal stem cell populations, we have identified osteogenic small molecules that can direct lineage-specific differentiation to an osteoblast phenotype," said Paul Grayson, president and CEO of Fate Therapeutics. "While current therapies focus on blocking bone degeneration, novel small molecules that promote bone formation represent the next-generation of therapeutic agents for osteo-regenerative medicine." Fate Therapeutics is utilizing its adult stem cell biology engine and induced pluripotent stem cell (iPSC) technology platform to develop Stem Cell Modulators (SCMs) - small molecules and biologics that guide cell fate for therapeutic purposes. Naturally-occurring adult stem cells, such as mesenchymal stem cells, can differentiate into a variety of cell types and are found in almost all tissues or organs in the body where they are primarily responsible for maintaining and repairing their native tissue. The ability of SCMs to promote bone regeneration may be applied to treat a number of bone injuries and conditions including non-union fracture, spinal fusion or osteoporosis. The Company"s poster entitled, "A small molecule activator of the canonical Wnt pathway stimulates differentiation of mesenchymal stem cells to an osteoblast phenotype," will be presented by Scott Thies, Ph.D., senior director of stem cell biology at Fate Therapeutics, at ISSCR on Friday, July 10 from 4:45 p.m. to 7:00 p.m. CEST. About Fate Therapeutics, Inc. Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate"s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with first access to the most advanced iPSC technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. Fate Therapeutics, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009